Table 2.
Comparison between Glucocorticoid Treated Group and Non-glucocorticoid Treated Group at Baseline.
| Patients treated with glucocorticoid (n=68) | Patients not treated with glucocorticoid (n=32) | p value | |
|---|---|---|---|
| Age (yr) | 67.4±1.6 69.5 [63.0-77.0] |
67.8±1.6 68.0 [62.0-75.5] |
0.5450 |
| Number of male/female | 6/62 | 1/31 | 0.4247 |
| Postmenopausal (%) | 56 (90.3) | 30 (96.8) | 0.4161 |
| Body mass index (kg/m2) | 20.8±0.4 20.2 [18.1-22.8] |
20.9±0.5 20.5 [18.8-22.6] |
0.6132 |
| Daily prednisolone-equivalent dose (mg/day) | 6.7±0.7 5.0 [3.3-8.0] | 0 | |
| Bone mineral density (g/cm2) | 0.76±0.11 | 0.75±0.09 | 0.4904 |
| Diagnosis, no. (%) | |||
| Rheumatoid arthritis | 26 (38.3) | 25 (78.2) | 0.0002 |
| Systemic lupus erythematosus | 14 (20.6) | 0 (0) | 0.0041 |
| Polymyalgia rheumatica | 10 (14.7) | 1 (3.1) | 0.1001 |
| Polymyositis/dermyositis | 4 (5.9) | 1 (3.1) | 0.9999 |
| Mixed connected tissue disease | 4 (5.9) | 0 (0) | 0.3029 |
| Sjögren’s syndrome | 2 (2.9) | 2 (6.3) | 0.5910 |
| Vasculitis syndrome | 3 (4.4) | 1 (3.1) | 0.9999 |
| Systemic scleroderma | 2 (2.9) | 1 (3.1) | 0.9999 |
| Others | 3 (4.4) | 1 (3.1) | 0.9999 |
| Pre-denosumab treatment, no. (%) | |||
| Bisphosphonates | 40 (58.8) | 20 (62.5) | 0.8279 |
| Teriparatide | 9 (13.2) | 1 (3.1) | 0.1618 |
| Vitamin D | 4 (5.9) | 4 (12.5) | 0.2637 |
| Vitamin K | 1 (1.4) | 2 (6.3) | 0.2393 |
| SERM | 2 (2.9) | 1 (3.1) | 0.9999 |
| Baseline of bone turnover markers | |||
| NTx (nmolBCE/L) | 16.1±0.8 13.9 [11.9-20.7] |
17.0±1.1 15.9 [13.0-20.3] |
0.3844 |
| TRACP-5b (mU/dL) | 260.5±21.5 231.5 [129.0-336.8] |
276.4±27.7 252.0 [160.0-351.5] |
0.5115 |
| P1NP (µg/L) | 32.0±4.1 25.3 [16.0-37.3] |
36.6±3.7 30.5 [19.2-53.3] |
0.0715 |
| BAP (µg/L) | 13.6±1.6 10.40 [8.4-14.4] |
13.8±1.2 12.1 [9.7-16.3] |
0.1104 |
| OC (ng/mL) | 6.6±0.6 5.3 [3.8-7.7] |
8.0±0.8 7.2 [5.1-9.9] |
0.0258 |
| Change of bone turnover markers (%) | |||
| Δ NTx | -20.9±4.1 -28.1 [-38.6- -8.1] |
-6.7±7.1 -20.3 [-47.4- 18.5] |
0.4671 |
| Δ TRACP-5b | -36.2±6.3 -51.1 [-65.2- -8.7] |
-45.0±11.0 -66.5 [-77.7- -49.2] |
0.0512 |
| Δ P1NP | -28.1±6.3 -39.9 [-62.7- -7.8] |
-31.2±10.7 -44.1 [-69.3- -18.2] |
0.4519 |
| Δ BAP | -8.8±14.7 -24.2 [-42.3- -12.4] |
-25.8±6.3 -30.6 [-52.2- -14.0] |
0.2874 |
| Δ OC | -2.1±10.9 -27.9 [-48.8- 7.8] |
15.0±32.0 -24.8 [-45.1- -7.8] |
0.8164 |
SERM: selective estrogen receptor modulators, NTx: N-telopeptide crosslinked of type I collagen, TRACP-5b: tartrate-resistant acid phosphatase isoform 5b, P1NP: procollagen type I N-terminal peptide, BAP: bone alkaline phosphatase, OC: osteocalcin, Δ: the rate of change during 12 months